{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:23:02Z","timestamp":1793485382978,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Tetraphase Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Expert guidelines discourage use of antipseudomonal \u03b2-lactams and fluoroquinolones in lower-risk patients with community-acquired complicated intra-abdominal infection (CA cIAI). Compliance with these recommendations across US hospitals is unclear. This study sought to determine treatment patterns and associated outcomes among adult hospitalized lower-risk patients with CA cIAI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A study using data from the Premier Healthcare Database (10\/2015\u201312\/2017) was performed. Inclusion criteria: age \u226518 years; hospitalized; had a cIAI at admission; and received antibiotics within the first 4 hospital days. Patients were excluded if they were high risk, were transferred from another health care facility, had a recent hospital admission, or received dialysis within 30 days of admission. Empiric antibiotic treatment patterns and associated outcomes were quantified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 46\u2005722 (66%) patients with cIAIs met the lower-risk CA IAI study criteria. Among lower-risk CA IAI patients, the mean (SD) age was 53.4 (18.2) years, and 71% had a Charlson Comorbidity Index score of 0. The most common diagnosis was acute appendicitis with peritonitis (59.7%). Among lower-risk CA IAI patients, 54% received piperacillin\/tazobactam, 20% received a fluoroquinolone (FQ), 11% received ceftriaxone, and 7% received ampicillin\/sulbactam. Overall, the median hospital length of stay was 4 days and median costs were $12\u2005345 USD. Nearly 90% of patients were discharged home, and &amp;lt;1% died. Outcomes were similar across all empiric treatments received.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Overuse of antipseudomonal \u03b2-lactams and fluoroquinolones was commonplace among lower-risk CA IAI patients. These findings can serve as the basis for an antimicrobial stewardship initiative in hospitals aspiring to reduce the use of broad-spectrum antibiotics.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaa237","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T22:53:29Z","timestamp":1592520809000},"source":"Crossref","is-referenced-by-count":11,"title":["An Evaluation of Treatment Patterns and Associated Outcomes Among Adult Hospitalized Patients With Lower-Risk Community-Acquired Complicated Intra-abdominal Infections: How Often Are Expert Guidelines Followed?"],"prefix":"10.1093","volume":"7","author":[{"given":"Thomas P","family":"Lodise","sequence":"first","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-7399","authenticated-orcid":false,"given":"Sergey","family":"Izmailyan","sequence":"first","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Olesky","sequence":"first","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-5216","authenticated-orcid":false,"given":"Kenneth","family":"Lawrence","sequence":"first","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"key":"2020071113041876600_CIT0001","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020071113041876600_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/sur.2016.261","article-title":"The surgical infection society revised guidelines on the management of intra-abdominal infection","volume":"18","author":"Mazuski","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"key":"2020071113041876600_CIT0003","author":"US Food and Drug Administration."},{"key":"2020071113041876600_CIT0004","author":"FDA Drug Safety Communication. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients"},{"key":"2020071113041876600_CIT0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/sur.2018.317","article-title":"An evaluation of guideline concordance in the management of intra-abdominal infections","volume":"20","author":"Nguyen","year":"2019","journal-title":"Surg Infect (Larchmt)"},{"key":"2020071113041876600_CIT0006"},{"key":"2020071113041876600_CIT0007","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofz475","article-title":"Comparisons of 30-day admission and 30-day total health care costs between patients who were treated with oritavancin or vancomycin for a skin infection in the outpatient setting","volume":"6","author":"Lodise","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020071113041876600_CIT0008","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofz504","article-title":"Carbapenem treatment and outcomes among patients with culture-positive complicated intra-abdominal infections in US hospitals: a retrospective cohort study","volume":"6","author":"Zilberberg","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020071113041876600_CIT0009","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2020071113041876600_CIT0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1179\/1973947814Y.0000000164","article-title":"Epidemiology and antimicrobial susceptibility of gram-negative aerobic bacteria causing intra-abdominal infections during 2010-2011","volume":"27","author":"Hawser","year":"2015","journal-title":"J Chemother"},{"key":"2020071113041876600_CIT0011","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1749-7922-9-37","article-title":"Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW study","volume":"9","author":"Sartelli","year":"2014","journal-title":"World J Emerg Surg"},{"key":"2020071113041876600_CIT0012","article-title":"The efficacy and safety of eravacycline in the treatment of complicated intra-abdominal infections: a systemic review and meta-analysis of randomized controlled trials","volume":"8:866","author":"Lan","year":"2019","journal-title":"J Clin Med"},{"key":"2020071113041876600_CIT0013","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020071113041876600_CIT0014","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"2020071113041876600_CIT0015","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/cid\/cix379","article-title":"The effect of a piperacillin\/tazobactam shortage on antimicrobial prescribing and Clostridium difficile risk in 88 US medical centers","volume":"65","author":"Gross","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020071113041876600_CIT0016","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"Mcdonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020071113041876600_CIT0017","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/TA.0b013e31823c5637","article-title":"Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients","volume":"72","author":"Shah","year":"2012","journal-title":"J Trauma Acute Care Surg"},{"key":"2020071113041876600_CIT0018","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/jac\/dkt489","article-title":"Medication risk factors associated with healthcare-associated Clostridium difficile infection: a multilevel model case-control study among 64 US academic medical centres","volume":"69","author":"Pakyz","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020071113041876600_CIT0019","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jmii.2017.08.015","article-title":"Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"51","author":"Tsao","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"2020071113041876600_CIT0020","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/jac\/dkr156","article-title":"Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae","volume":"66","author":"Patel","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2020071113041876600_CIT0021","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1086\/518972","article-title":"Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates","volume":"28","author":"Lodise","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020071113041876600_CIT0022","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/cid\/ciy936","article-title":"Gastrointestinal microbiota disruption and risk of colonization with carbapenem-resistant Pseudomonas aeruginosa in ICU patients","volume":"69","author":"Pettigrew","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020071113041876600_CIT0023","doi-asserted-by":"crossref","first-page":"S719","DOI":"10.1093\/ofid\/ofy210.2060","article-title":"Emerging piperacillin\/tazobactam resistance in Escherichia coli and Klebsiella sp","volume":"5","author":"Suseno","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2020071113041876600_CIT0024","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/phar.2201","article-title":"Duration of exposure to antipseudomonal beta-lactam antibiotics in the critically ill and development of new resistance","volume":"39","author":"Teshome","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2020071113041876600_CIT0025","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020071113041876600_CIT0026","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/archinternmed.2012.1690","article-title":"Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial","volume":"172","author":"Carratal\u00e0","year":"2012","journal-title":"Arch Intern Med"},{"key":"2020071113041876600_CIT0027","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1086\/656431","article-title":"Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship","volume":"51","author":"Jenkins","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020071113041876600_CIT0028"},{"key":"2020071113041876600_CIT0029","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijsu.2010.06.016","article-title":"Peritoneal fluid culture in appendicitis: review in changing times","volume":"8","author":"Davies","year":"2010","journal-title":"Int J Surg"},{"key":"2020071113041876600_CIT0030","article-title":"Small differences in sepsis and SIRS guidelines can result in major differences in reimbursement","author":"Kulanko"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa237\/33404757\/ofaa237.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/7\/ofaa237\/33486728\/ofaa237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/7\/ofaa237\/33486728\/ofaa237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T17:04:31Z","timestamp":1594487071000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa237\/5859615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa237","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,6,19]]},"article-number":"ofaa237"}}